





CanAssift-Breast : Risk Stratification Test


Morphometric IHC-based test to stratify breast cancer patients based on risk of recurrence. CanAssist-Breast integrates IHC data and clinical parameters into a statistical algorithm which provides CanAssist-Breast (CAB) score that stratifies patients as "low-risk" or "high-risk" for distant recurrence over 5 years.



Clinical Validation: Kaplan-Meier Survival Analysis




Risk stratification independent of nodal status



CanAssist-Breast is an independent predictor of prognosis

Multivariate Cox Model	Hazard Ratio	P-value
Age	1.47	0.16
ER	0.97	0.93
PR	1.65	0.07
Treatment modality	0.70	0.27
CanAssi f t-Breast	3.44	<0.0001

Chemotherapy Benefit for high-risk patients




Absolute chemotherapy benefit for high-risk patients: 22%

CanAssift-Breast vs Competing Products

	Oncotype Dx	Mammaprin	t Prosigna	Endopredict	CanAssi f t-Breast
Indicated for	ER+/PR+/HER2-, stage I, II, lymph node-negative (N0), and 1-3 nodes positive (N1)			ER+/PR+/HER2 – ; lymph node N0 & N1, Stage 1, 2	
Genes Used	Primarily ER, PR, HER2 and proliferation based genes			Breast cancer metastasis pathways - invasion, stem cells, drug resistance, indicators of proliferation - tumor grade	
Risk- stratification	>40% patients in intermediate zone	No intermediate zone	>30% patients in intermediate zone	No intermediate zone	No intermediate zone
Outcome	Prognostic and CT- predictive	Prognostic	Prognostic	Prognostic	Prognostic and predictive of chemotherapy benefit
TAT	21 days	21 days	21 days	21 days	10 days
Regulatory Approvals	Only CLIA certified	FDA 510(k), CE Mark	FDA 510(k), CE Mark	CE Mark	ISO 13485, CE Mark. Performed in NABL-accredited laboratory
Price USD	4000	4000	2200	2200	Most affordable

CanAssift-Breast : looks beyond proliferation pathways



Case Studies

Patient 1

Age: 50 Years.

Diagnosis: HR+/HER2-/ Grade II/node-negative IDC of breast, Stage 2, Ki 67: 45%

Standard Treatment: Surgery + Chemotherapy + Radiation Therapy + Hormonal Therapy

CanAssift-Breast Score 7.1

CanAssist-Breast classified her as **low-risk** with no added benefit of chemotherapy.

Patient's treatment planned accordingly.

Patient 2

Age: 50 Years.

Diagnosis: HR+/HER2-/ Grade II/node-negative IDC of breast, Stage 1, Ki 67: 20%

Standard Treatment: Surgery + Chemotherapy + Radiation Therapy + Hormonal Therapy


CanAssift-Breast Score 20

CanAssist-Breast classified her as high-risk and can benefit from chemotherapy.

Patient's treatment planned accordingly.

CanAssift-Breast (E







Contact Information

Oncostem Diagnostics Pvt. Ltd. #4, Raja Ram Mohan Roy Road, Aanand Tower, 2nd floor, South wing, Bangalore – 560027.

> +91 96866 96505 +91 80 222 400 34

info@oncostemdiagnostics.com

www.oncostemdiagnostics.com